Literature DB >> 23743931

Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts.

Marina N Nikiforova1, Asif Khalid, Kenneth E Fasanella, Kevin M McGrath, Randall E Brand, Jennifer S Chennat, Adam Slivka, Herbert J Zeh, Amer H Zureikat, Alyssa M Krasinskas, N Paul Ohori, Karen E Schoedel, Sarah Navina, Geeta S Mantha, Reetesh K Pai, Aatur D Singhi.   

Abstract

With improvements in abdominal imaging, detection of incidental pancreatic cysts are becoming increasingly common. Analysis of pancreatic cyst fluid from fine-needle aspiration is particularly important in identifying intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), which have significant implications in clinical intervention and follow-up. Previous controlled studies have shown that KRAS mutations in cyst fluid are highly specific for mucinous differentiation in pancreatic cysts; however, this has not been examined in the clinical setting. Over a 6-year study period, 618 pancreatic cyst fluids obtained by fine-needle aspiration at the time of endoscopic ultrasound were tested for KRAS mutations as part of routine evaluation for a cystic neoplasm. Of the 618 specimens, 603 (98%) from 546 patients were satisfactory for molecular analysis. Patients ranged in age from 17 to 90 years (mean, 63.9 years) and were predominantly female (68%). Pancreatic cysts were relatively evenly distributed throughout the pancreas and ranged in size from 0.6 to 11.0 cm (mean, 2.3 cm). Mutations in KRAS were detected in 232 of 603 (38%) aspirates. Although sufficient for molecular analysis, 320 of 603 (53%) specimens were either less than optimal (38%) or unsatisfactory (15%) for cytopathologic diagnosis. Surgical follow-up information was available for 142 (26%) patients and consisted of 53 KRAS-mutated and 89 KRAS-wild-type cysts. Overall, KRAS mutations had a specificity of 100%, but a sensitivity of 54% for mucinous differentiation. When stratified by cyst type, KRAS had a sensitivity of 67% and 14% for IPMNs and MCNs, respectively. In summary, KRAS mutations were highly specific for mucinous differentiation, but were inadequate in identifying MCNs. Future molecular studies and the combination of other fluid markers are required to improve the detection and classification of pancreatic mucinous neoplasms by endoscopic ultrasound fine-needle aspiration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23743931     DOI: 10.1038/modpathol.2013.91

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  38 in total

Review 1.  Clinical approach to incidental pancreatic cysts.

Authors:  Austin L Chiang; Linda S Lee
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 2.  Does EUS-FNA molecular analysis carry additional value when compared to cytology in the diagnosis of pancreatic cystic neoplasm? A systematic review.

Authors:  Amy Gillis; Ilaria Cipollone; Grainne Cousins; Kevin Conlon
Journal:  HPB (Oxford)       Date:  2014-11-27       Impact factor: 3.647

Review 3.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk.

Authors:  Annabelle L Fonseca; Kimberly Kirkwood; Michael P Kim; Anirban Maitra; Eugene J Koay
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

Review 4.  Endosonography in the diagnosis and management of pancreatic cysts.

Authors:  Vivek Kadiyala; Linda S Lee
Journal:  World J Gastrointest Endosc       Date:  2015-03-16

Review 5.  Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Marina Paini; Stefano Crippa; Stefano Partelli; Filippo Scopelliti; Domenico Tamburrino; Andrea Baldoni; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Incidental Cystic Lesions in the Pancreas: Resect? EUS? Follow?

Authors:  Linda S Lee
Journal:  Curr Treat Options Gastroenterol       Date:  2014-09

Review 7.  Diagnosis and Management of Pancreatic Cystic Neoplasms.

Authors:  Malcolm Kearns; Nuzhat A Ahmad
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

Review 8.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

9.  KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound.

Authors:  James R Eshleman; Alexis L Norris; Yoshihiko Sadakari; Marija Debeljak; Michael Borges; Colleen Harrington; Elaine Lin; Aaron Brant; Thomas Barkley; J Alejandro Almario; Mark Topazian; James Farrell; Sapna Syngal; Jeffrey H Lee; Jun Yu; Ralph H Hruban; Mitsuro Kanda; Marcia Irene Canto; Michael Goggins
Journal:  Clin Gastroenterol Hepatol       Date:  2014-12-04       Impact factor: 11.382

Review 10.  Early detection of pancreatic cancer using DNA-based molecular approaches.

Authors:  Aatur D Singhi; Laura D Wood
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-07       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.